8 Aug 2013 07:00
8 AUGUST 2013
Akers Biosciences, Inc.
("ABI"or the "Company")
Proposed NASDAQ Listing
NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION OR DISSEMINATION IN OR INTO OR FROM THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION
Akers Biosciences, Inc. (AIM:AKR), a leading designer and manufacturer of rapid diagnostic screening and testing products, announces that it is seeking a listing of the Company's shares on The NASDAQ Capital Market ("NASDAQ"). Simultaneous with the NASDAQ listing, the Company is also seeking to raise additional capital via a registered public offering (the "Offering") of approximately $15,000,000 of its common stock (the "Securities"). The Company has today has filed with the US Securities and Exchange Commission ("SEC") a registration statement on Form S-1 relating to the proposed Offering.
A registration statement relating to these Securities has been filed with the Securities and Exchange Commission but has not yet become effective. These Securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective.
The registration statement filed by the Company may be viewed on the SEC's website at sec.gov.
There are no assurances that the Company will be listed on NASDAQ or that the Offering will be completed.
The Company will update the market on any progress towards the proposed NASDAQ listing.
About Akers Biosciences, Inc.
Akers Biosciences develops, manufactures, and supplies rapid, point‐of‐care screening and testing products designed to bring health status information, both rapidly and directly, to the consumer or healthcare provider. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The Company's state‐of‐the‐art rapid diagnostic assays can be performed virtually anywhere, in minutes, since time is always of essence. ABI is aligned with high volume medical product distributors to help facilitate the Company's growth into a major, worldwide competitor in the field of rapid diagnostics. Additional information on the Company and its products can be found at www.akersbiosciences.com
Enquiries:
Thomas A. Nicolette
President and CEO
Tel. +1 856 848 8698
Antony Legge or James Thomas
Daniel Stewart & Company plc (Nomad and Broker)
Tel. +44 (0)20 7776 6550
*Daniel Stewart & Company plc is not acting for the Company in respect of the Offering.